Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus continued prednisolone for steroid-unresponsive idiopathic nephrotic syndrome after 8 weeks
NL-OMON44222Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab and prednisolone in Idiopathic nephrotic syndrome (INS), nephrosis and focal segmental glomerulosclerosis (FSGS), sponsored by Radboud University Medical Center. Started Aug 2018; status: recruiting.
02
Drugs
rituximabprednisolone
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NL-OMON44222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44222.